India, July 8 -- Rhythm Pharmaceuticals, Inc. (RYTM), announced that results from its pivotal Phase 3 TRANSCEND trial of Setmelanotide in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM).
Acquired hypothalamic obesity is a rare condition that can occur following hypothalamic injury, leading to accelerated and sustained weight gain. Patients often face limited treatment options, making effective therapies a critical need.
The TRANSCEND study, the largest and longest placebo-controlled trial conducted in this patient population, enrolled adults and children aged four years and older. Over 52 weeks, patients treated with Setmelanotide achieved a placebo-adjusted BMI reduction of 19...